KR960703598A - 신경 질환 치료제(agent for curing neurotic diseases) - Google Patents

신경 질환 치료제(agent for curing neurotic diseases) Download PDF

Info

Publication number
KR960703598A
KR960703598A KR1019960700688A KR19960700688A KR960703598A KR 960703598 A KR960703598 A KR 960703598A KR 1019960700688 A KR1019960700688 A KR 1019960700688A KR 19960700688 A KR19960700688 A KR 19960700688A KR 960703598 A KR960703598 A KR 960703598A
Authority
KR
South Korea
Prior art keywords
formula
neurological diseases
phenyl
alkyl
group
Prior art date
Application number
KR1019960700688A
Other languages
English (en)
Inventor
이노꾸찌 지니찌
구로다 요이찌로
무라모또 가즈오
야마다 하루끼
우스끼 세이고우
Original Assignee
와따루 야마야
세이까가꾸 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 와따루 야마야, 세이까가꾸 코포레이션 filed Critical 와따루 야마야
Publication of KR960703598A publication Critical patent/KR960703598A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings

Abstract

유효 성분으로서 다음 식(Ⅰ)으로 표시된 2-아실아미노프로판올 유도체 또는 약리적으로 허용되는 그의 염으로 이루어진, 말초신경계 또는 중추신경계의 장해에 의해 원인이 된 신경 질환의 치료제가 개시된다 :
상기 식에서, R1은 알킬, 알콕시, 히드록시 및 니트로 중에서 선택된 같거나 서로 다른 치환제 1∼3개에 의해 각각 치환될 수 있는 페닐기 또는 시클로헥실기를 나타내거나, 알킬기를 나타내며, n이 0∼16의 정수를 나타낸다.
신경 세포의 내생 스핑고글리코리피드, 특히 강글릴오시드의 생합성을 상승시킴으로서 축색 확장 및 시냅스형성을 촉진하고, 이에 의해 그것을 중추신경계 및 말초신경계의 여러가지 질병을 치료하는데 사용할 수 있다.

Description

신경 질환 치료제(AGENT FOR CURING NEUROTIC DISEASES)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (20)

  1. 유효 성분으로서 다음 식(Ⅰ)으로 표시된 2-아실아미노프로판올 유도체 또는 약리적으로 허용되는 그의 염으로 이루어진, 말초신경계 또는 중추신경계의 장해에 의해 원인이 된 신경 질환의 치료제:
    상기 식에서, R1은 알킬, 알콕시, 히드록시 및 니트로 중에서 선택된 같거나 서로 다른 치환제 1∼3개에 의해 각각 치환될 수 있는 페닐기 또는 시클로헥실기를 나타내거나, 알킬기를 나타내고, n이 0∼16의 정수를 나타낸다.
  2. 제1항에 있어서, 식(Ⅰ)의 n이 6∼16인 신경 질환의 치료제.
  3. 제1항에 있어서, 식(Ⅰ)의 R1이 페닐기인 신경 질환의 치료제.
  4. 제1항에 있어서, 식(Ⅰ)으로 표시된 2-아실아미노프로판을 유도체가 L-threo 이성체인 신경 질환 치료제.
  5. 제4항에 있어서, 2-아실아미노프로판올 유도체가 1-페닐-2-데칸올아미노-3-모르폴리노-1-프로판올의 L-trreo 이성체, 또는 그의 염인 신경 질환의 치료제.
  6. 말초신경계 또는 중추신경계의 장해에 의해 원인이 된 신경 질환에 걸린 포유류에 다음 식(Ⅰ)으로 표시된 2-아실아미노프로판을 유도체 또는 약리적으로 허용되는 그의 염을 글리코스핑고리피드의 생합성을 촉진하고, 축색 확장을 촉진하고 및/또는 시냅스 형성을 촉진하기 위한 유효량으로 투여하는 것으로 이루어진, 신경 질환의 치료방법 :
    상기 식에서 R1은 알킬, 알콕시, 히드록시 및 니트로 중에서 선택된 같거나 서로 다른 치환제 1∼3개에 의해 각각 치환될 수 있는 페닐기 또는 시클로헥실기를 나타내거나, 알킬기를 나타내고, n이 0∼16의 정수를 나타낸다.
  7. 제6항에 있어서, 식(Ⅰ)의 n이 6∼16인 신경 질환의 치료방법.
  8. 제6항에 있어서, 식(Ⅰ)의 R1이 페닐기인 신경 질환의 치료방법.
  9. 제6항에 있어서, 식(Ⅰ)으로 표시된 2-아실아미노프로판을 유도체가 L-threo 이성체인 신경 질환의 치료방법.
  10. 제9항에 있어서, 2-아실아미노프로판올 유도체가 1-페닐-2-데칸올아미노-3-모르폴리노-1-프로판올의 L-trreo 이성체, 또는 그의 염인 신경 질환의 치료방법.
  11. 말초신경계 또는 중추신경계의 장해에 의해 원인이 된 신경 질환에 치료제를 제조하기 위한, 다음 식(Ⅰ)으로 표시된 2-아실아미노프로판올 유도체, 약리적으로 허용되는 그의 염 또는 그들 두가지 모두로 이루어진 의약 조성물의 용도:
    상기 식에서, R1은 알킬, 알콕시, 히드록시 및 니트로 중에서 선택된 같거나 서로 다른 치환제 1∼3개에 의해 각각 치환될 수 있는 페닐기 또는 시클로헥실기를 나타내거나, 알킬기를 나타내며, n이 0∼16의 정수를 나타낸다.
  12. 제11항에 있어서, 식(Ⅰ)의 n이 6∼16인 용도.
  13. 제11항에 있어서, 식(Ⅰ)의 R1이 페닐기인 용도.
  14. 제11항에 있어서, 식(Ⅰ)으로 표시된 2-아실아미노프로판올 유도체가 L-threo 이성체인 용도.
  15. 제14항에 있어서, 2-아실아미노프로판올 유도체가 1-페닐-2-데칸올아미노-3-모르폴리노-1-프로판올의 L-trreo 이성체, 또는 그의 염인 용도.
  16. 다음 식(Ⅰ)으로 표시된 적어도 한가지의 2-아실아미노프로판올 유도체 또는 약리적으로 허용되는 그의 염 및 포스포리피드로 이루어진, 신경 질환을 치료하기 위한 리포좀 제제 조성물:
    상기 식에서 R1은 알킬, 알콕시, 히드록시 및 니트로 중에서 선택된 같거나 서로 다른 치환제 1∼3개에 의해 각각 치환될 수 있는 페닐기 또는 시클로헥실기를 나타내거나, 알킬기를 나타내고, n이 0∼16의 정수를 나타낸다.
  17. 제16항에 있어서, 식(Ⅰ)의 n이 6∼16인 리포좀 제제 조성물.
  18. 제16항에 있어서, 식(Ⅰ)의 R1이 페닐기인 리포좀 제제 조성물.
  19. 제16항에 있어서, 식(Ⅰ)으로 표시된 2-아실아미노프로판올 유도체가 L-threo 이성체인 리포좀제제 조성물.
  20. 제19항에 있어서, 2-아실아미노프로판올 유도체가 1-페닐-2-데칸올아미노-3-모르폴리노-1-프로판올의 L-trreo 이성체, 또는 그의 염인 리포좀 제제 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960700688A 1993-08-13 1994-08-12 신경 질환 치료제(agent for curing neurotic diseases) KR960703598A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP220518/1993 1993-08-13
JP22051893 1993-08-13
PCT/JP1994/001342 WO1995005177A1 (fr) 1993-08-13 1994-08-12 Remede contre les maladies nerveuses

Publications (1)

Publication Number Publication Date
KR960703598A true KR960703598A (ko) 1996-08-31

Family

ID=16752277

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960700688A KR960703598A (ko) 1993-08-13 1994-08-12 신경 질환 치료제(agent for curing neurotic diseases)

Country Status (12)

Country Link
US (2) US5707649A (ko)
EP (1) EP0720852B1 (ko)
JP (1) JP3778926B2 (ko)
KR (1) KR960703598A (ko)
CN (1) CN1128951A (ko)
AT (1) ATE197672T1 (ko)
AU (1) AU676361B2 (ko)
DE (1) DE69426331T2 (ko)
HU (1) HUT73527A (ko)
NO (1) NO960380L (ko)
NZ (1) NZ269847A (ko)
WO (1) WO1995005177A1 (ko)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT73527A (en) * 1993-08-13 1996-08-28 Seikagaku Kogyo Co Ltd Remedy for nervous diseases
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US6017887A (en) * 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
NO965193L (no) * 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
US5972928A (en) * 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
US6440455B1 (en) * 1997-09-02 2002-08-27 Children's Medical Center Corporation Methods for modulating the axonal outgrowth of central nervous system neurons
US6723838B1 (en) 1998-04-22 2004-04-20 Johns Hopkins University Signal transducing synaptic molecules and uses thereof
DE69939651D1 (de) 1998-06-29 2008-11-13 Los Angeles Childrens Hospital Behandlung hyperproliferativer erkrankungen
US6368831B1 (en) 1998-06-29 2002-04-09 Childrens Hospital Los Angeles Treatment of hyperproliferative disorders
AU756008B2 (en) * 1998-07-27 2003-01-02 Johns Hopkins University, The Methods for treating conditions modulated by lactosylceramide
US6635281B2 (en) * 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
EP1384719A1 (en) * 1999-07-09 2004-01-28 The Regents of The University of Michigan Inhibitors of the glucosyl ceramide synthase enzyme useful for the treatment of cancers, sphingolipidosis and microbial infections
US6407064B2 (en) 1999-12-06 2002-06-18 Seikagaku Corporation Aminoalcohol derivative and medicament comprising the same
JP5009459B2 (ja) * 1999-12-06 2012-08-22 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
US20100261159A1 (en) 2000-10-10 2010-10-14 Robert Hess Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof
BR0206400A (pt) * 2001-01-10 2005-01-18 Univ Michigan Compostos de amino ceramidas e seus usos em métodos terapêuticos
JP3742602B2 (ja) * 2001-05-09 2006-02-08 株式会社カネカ 還元型補酵素ｑの安定な溶液
PT2266968E (pt) * 2001-07-16 2013-02-25 Genzyme Corp Síntese de udp-glucose: inibidores de n-acil esfingosinaglucosiltransferase
US6916802B2 (en) * 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20060217560A1 (en) * 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
US7834147B2 (en) * 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
DE10352450A1 (de) * 2003-11-07 2005-06-23 Ruprecht-Karls-Universität Heidelberg Neues Mittel zur prophylaktischen und/oder therapeutischen Behandlung von Morbus Alzheimer
DE10352449A1 (de) * 2003-11-07 2005-06-16 Ruprecht-Karls-Universität Heidelberg Mittel zur prophylaktischen und/oder therapeutischen Behandlung von Morbus Alzheimer
US8912144B2 (en) * 2003-12-16 2014-12-16 Children's Medical Center Corporation Method for treating stroke via administration of NEP1-40 and inosine
US20090111812A1 (en) * 2004-06-14 2009-04-30 Musc Foundation For Research Development Methods for treating inflammatory disorders
BRPI0517701A8 (pt) * 2004-11-10 2018-01-23 Genzyme Corp métodos de tratamento de diabetes mellitus
CN101151248B (zh) * 2005-01-26 2012-06-20 阿勒根公司 具有镇痛活性和/或免疫刺激物活性的3-芳基-3-羟基-2-氨基丙酸酰胺类、3-杂芳基-3-羟基-2-氨基丙酸酰胺类以及相关化合物
EP1857112B1 (en) * 2005-03-09 2013-05-15 Sunstar Inc. Anticancer composition comprising liposomes containing phytosterols
CA2650691C (en) * 2006-04-28 2015-10-06 Children's Hospital Medical Center Fusogenic properties of saposin c and related proteins and peptides for application to transmembrane drug delivery systems
ES2546181T3 (es) * 2006-05-09 2015-09-21 Genzyme Corporation Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos
WO2008011487A2 (en) * 2006-07-19 2008-01-24 Allergan, Inc. L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain
WO2008011483A2 (en) * 2006-07-19 2008-01-24 Allergan, Inc. Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds
US20100190792A1 (en) * 2007-03-06 2010-07-29 Allergan, Inc Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
WO2008150486A2 (en) 2007-05-31 2008-12-11 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
WO2009045503A1 (en) 2007-10-05 2009-04-09 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
US8389517B2 (en) 2008-07-28 2013-03-05 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
EP2349255B1 (en) 2008-10-03 2016-03-30 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
JPWO2010087313A1 (ja) * 2009-01-29 2012-08-02 株式会社林原生物化学研究所 神経突起伸展促進剤
CA2817198C (en) * 2009-11-12 2018-05-01 Texas Tech University Compositions and methods for treating hyperproliferative disorders
AU2010324810B2 (en) 2009-11-27 2016-05-12 Genzyme Corporation An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
US9134315B2 (en) 2010-02-12 2015-09-15 The Johns Hopkins University Use of the lactosylceramide synthase isoform B1,4GalT-V as a biomarker for cancer
WO2016126572A2 (en) 2015-02-02 2016-08-11 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
EP3501495A1 (en) * 2017-12-21 2019-06-26 InnoMedica Holding AG Liposomes comprising sphingomyelin
JP2022553107A (ja) 2019-10-23 2022-12-21 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン グルコシルセラミドシンターゼ阻害剤およびそれを使用する治療方法
US20230212123A1 (en) 2020-04-28 2023-07-06 The Regents Of The University Of Michigan Pyridine Inhibitors of Glucosylceramide Synthase and Therapeutic Methods Using the Same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963297A (en) * 1987-12-22 1990-10-16 The Liposome Company, Inc. Spontaneous vesticulation of multilamellar liposomes
US5041441A (en) * 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
HUT73527A (en) * 1993-08-13 1996-08-28 Seikagaku Kogyo Co Ltd Remedy for nervous diseases

Also Published As

Publication number Publication date
HUT73527A (en) 1996-08-28
AU676361B2 (en) 1997-03-06
CN1128951A (zh) 1996-08-14
DE69426331D1 (de) 2000-12-28
US5707649A (en) 1998-01-13
AU7350694A (en) 1995-03-14
HU9600278D0 (en) 1996-04-29
WO1995005177A1 (fr) 1995-02-23
NO960380D0 (no) 1996-01-30
NO960380L (no) 1996-03-14
JP3778926B2 (ja) 2006-05-24
NZ269847A (en) 1996-11-26
DE69426331T2 (de) 2001-06-21
EP0720852B1 (en) 2000-11-22
US5849326A (en) 1998-12-15
EP0720852A4 (en) 1997-07-23
EP0720852A1 (en) 1996-07-10
ATE197672T1 (de) 2000-12-15

Similar Documents

Publication Publication Date Title
KR960703598A (ko) 신경 질환 치료제(agent for curing neurotic diseases)
HN1998000074A (es) Derivados de macrolidos c-4 sustituidos
ATE52498T1 (de) Amidderivate.
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
ES511986A0 (es) "un procedimiento para la preparacion de nuevas 1,2,3,4 tetrahidro 2 naftilaminas".
KR940005274A (ko) 쇼그렌(Sjoegren)증후군 치료제
KR950016727A (ko) 트롬보모듈린 발현을 증가시키는 방법
KR970707140A (ko) 평활근 세포 증식 억제제(Smooth muscle cell proliferation inhibitors)
EP0361791A3 (en) Azacyclic derivatives useful as medicaments
KR880013886A (ko) 신규 알칸술폰아닐리드 유도체, 그의 제조방법 및 이를 함유하는 제약 조성물
KR950032171A (ko) 옥소피리디닐퀴녹살린 유도체
ATE160143T1 (de) 2-substituierte morpholin- und thiomorpholinderivate als gaba-b antagonisten
FR2707089B1 (fr) Nouveaux dérivés d'acide phosphonique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
PT89274A (pt) Processo para a preparacao de novos analogos de mitomicina substituidos em posicao 6 e de composicoes farmaceuticas que os contem
PT89757A (pt) Processo para a preparacao de novos derivados da xantina e de composicoes farmaceuticas que os contem, uteis no tratamento da ulcera peptica
KR940701251A (ko) 콜레스테롤-강하 토코페롤 동족체
FI953260A (fi) Farmaseuttiset koostumukset ja menetelmä niiden valmistamiseksi
BR9813775A (pt) Uso de um composto, processo para o tratamento de uma condição de cefaléia vascular, e, composição farmacêutica adequada para uso no tratamento de uma condição de cefaléia vascular.
KR950032194A (ko) 신규푸린유도체 및 그 약학적으로 허용되는 염
KR950008502A (ko) 3-또는4-클리코실옥시벤조피란 유도체 및 활성 성분으로서 이를 함유하는 알러지치료제
BRPI0204489B8 (pt) "derivado de rodamina, composição farmacêutica, intermediário, e, processo para a síntese de novos derivados rodamina".
KR970064604A (ko) 벤조피란 유도체 및 그의 심장질환 치료제로서의 용도
KR930703013A (ko) 항당뇨병제로서 유용한 신규한 글루코하이드롤라제 억제제
KR950703955A (ko) 테르피리딘 유도체의 약학적 용도
RU96105023A (ru) Агент для лечения нейрональных заболеваний

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid